<?xml version='1.0' encoding='utf-8'?>
<document id="16118767"><sentence text="P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments."><entity charOffset="32-43" id="DDI-PubMed.16118767.s1.e0" text="risperidone" /><entity charOffset="48-64" id="DDI-PubMed.16118767.s1.e1" text="9-OH-risperidone" /><pair ddi="false" e1="DDI-PubMed.16118767.s1.e0" e2="DDI-PubMed.16118767.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16118767.s1.e0" e2="DDI-PubMed.16118767.s1.e1" /></sentence><sentence text="The drug transporter P-glycoprotein (P-gp) influences drug distribution across the blood-brain barrier (BBB) by actively extruding drugs into the neural capillaries" /><sentence text=" Several psychotropic drugs, including nortriptyline (NT) and risperidone (Risp), are substrates of P-gp"><entity charOffset="39-52" id="DDI-PubMed.16118767.s3.e0" text="nortriptyline" /><entity charOffset="54-56" id="DDI-PubMed.16118767.s3.e1" text="NT" /><entity charOffset="62-73" id="DDI-PubMed.16118767.s3.e2" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.16118767.s3.e0" e2="DDI-PubMed.16118767.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16118767.s3.e0" e2="DDI-PubMed.16118767.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16118767.s3.e0" e2="DDI-PubMed.16118767.s3.e2" /><pair ddi="false" e1="DDI-PubMed.16118767.s3.e1" e2="DDI-PubMed.16118767.s3.e1" /><pair ddi="false" e1="DDI-PubMed.16118767.s3.e1" e2="DDI-PubMed.16118767.s3.e2" /></sentence><sentence text=" Here we compared the in vitro P-gp interactions of Risp and its major metabolite, 9-OH-Risperidone (OH-Risp), with their distribution over the BBB in P-gp knock-out mice and in rats where P-gp was inhibited"><entity charOffset="83-99" id="DDI-PubMed.16118767.s4.e0" text="9-OH-Risperidone" /></sentence><sentence text=" K(m) and V(max) were determined by an in vitro ATPase assay, and V(max)/K(m) ratios of 2" /><sentence text="7 and 0" /><sentence text="5 were recorded for Risp and OH-Risp, respectively, suggesting that Risp is a better substrate for P-gp than OH-Risp" /><sentence text=" In Mdr1a (-/-) knock-out mice, the brain-serum ratios of both Risp and OH-Risp were more than ten times those of control mice (14 and 11, respectively)" /><sentence text=" When P-gp was inhibited with cyclosporine A (CsA) in Wistar rats, the effect was an order of magnitude less than that observed for the knock-out mice experiments (1-1"><entity charOffset="30-44" id="DDI-PubMed.16118767.s9.e0" text="cyclosporine A" /><entity charOffset="46-49" id="DDI-PubMed.16118767.s9.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.16118767.s9.e0" e2="DDI-PubMed.16118767.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16118767.s9.e0" e2="DDI-PubMed.16118767.s9.e1" /></sentence><sentence text="5 times the controls), and co-administration of NT had no effect"><entity charOffset="48-50" id="DDI-PubMed.16118767.s10.e0" text="NT" /></sentence><sentence text=" In conclusion, both Risp and OH-Risp interact with P-gp in vitro, and P-gp has a profound effect on Risp and OH-Risp distribution over the BBB, as is evident from the knock-out mice experiments" /><sentence text=" Drug-drug interaction effects in relation to P-gp, however, appear to be more limited" /><sentence text="" /></document>